<DOC>
	<DOCNO>NCT00593450</DOCNO>
	<brief_summary>The purpose study evaluate relative efficacy safety treatment neovascular AMD Lucentis fix schedule , Avastin fix schedule , Lucentis variable schedule , Avastin variable schedule . A five year follow-up visit conduct 2014 gather information long term outcome .</brief_summary>
	<brief_title>Comparison Age-related Macular Degeneration Treatments Trials : Lucentis-Avastin Trial</brief_title>
	<detailed_description>Age relate macular degeneration ( AMD ) lead cause severe vision loss people age 65 United States Western country . More 1.6 million people US currently one eye affect advanced stage AMD . Lucentis® effective treatment neovascular AMD study date . Bevacizumab ( Avastin® ) Lucentis® derive monoclonal antibody . Following encourage clinical trial result Lucentis® , several investigator begin evaluate intravitreal Avastin® treatment CNV . Given molecular similarity Lucentis , low cost , availability , interest Avastin® considerable . Avastin® evaluate relative Lucentis® . In addition , previous study answer question whether reduced dose schedule effective fix schedule monthly injection . Treatment dependent clinical response potential reduce treatment burden patient well reduce overall cost therapy . Only single eye patient analyze . At five year follow-up visit , subject undergo examination procedure original study ; however , five year follow-up visit deos involve study treatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Active , subfoveal choroidal neovascularization ( CNV ) Fibrosis &lt; 50 % total lesion area Visual acuity ( VA ) 20/2520/320 Age ≥ 50 yr At least 1 drusen ( &gt; 63μ ) either eye late AMD fellow eye Previous treatment CNV study eye Other progressive retinal disease likely compromise VA Contraindications injection Lucentis Avastin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>choroidal neovascularization</keyword>
</DOC>